Amended Statement of Changes in Beneficial Ownership (4/a)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Redmile Group, LLC	2. Issuer Name and Ticker or Trading Symbol Science 37 Holdings, Inc. [ SNCE ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300	3. Date of Earliest Transaction (MM/DD/YYYY) 10/6/2021
(Street) SAN FRANCISCO, CA 94129 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY) 10/8/2021	6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock ⁽²⁾	10/6/2021		A		14808234 ⁽¹⁾⁽²⁾⁽³⁾	A	⁽²⁾	19808234	I	See footnote ⁽⁴⁾

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:
(1)	On October 8, 2021, the Reporting Persons filed a Form 4 that inadvertently misstated the amount of securities acquired and beneficially owned. This amendment reports the shares of the Issuer's Common Stock issued to the Redmile Funds based on the corrected exchange ratio listed in footnote (3) below.
(2)	On October 6, 2021, pursuant to the agreement and plan of merger, dated May 6, 2021 (the "Merger Agreement"), LifeSci Acqisition II Corp. ("LSAQ" or "Issuer"), LifeSci Acquisition II Merger Sub, Inc. ("Merger Sub") and Science 37, Inc. ("Science 37") consummated a business combination (the "Business Combination"), in which Merger Sub merged with and into Science 37 with Science 37 surviving the merger as a wholly-owned subsidiary of LSAQ (which subsequently changed its name to "Science 37 Holdings, Inc.").
(3)	Pursuant to the terms of the Merger Agreement, the investors in Science 37 ("Legacy Investors") at the effective time of the Merger received approximately 1.815 shares of Issuer's Common Stock for each share of common stock of Science 37 held by them immediately prior to the effective time and a contingent right to additional shares of Issuer's Common Stock as described in Note 3 below, subject to the terms of the Merger Agreement. The Legacy Investors included certain private investment vehicles managed by Redmile Group, LLC (each, a "Redmile Fund").
(4)	These securities are directly owned by the Redmile Funds and may be deemed beneficially owned by Redmile Group, LLC ("Redmile") as investment manager of the Redmile Funds. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (collectively, the "Reporting Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Reporting Persons are a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Remarks:
Robert Faulkner, a member of the board of directors of the Issuer and a managing director of Redmile, was appointed to the board of the Issuer as a representative of Redmile. As a result, the Reporting Persons are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Redmile Group, LLC ONE LETTERMAN DRIVE, BUILDING D SUITE D3-300 SAN FRANCISCO, CA 94129	X	X
Green Jeremy C/O REDMILE GROUP, LLC ONE LETTERMAN DRIVE, BLDG D SUITE D3-300 SAN FRANCISCO, CA 94129		X

Signatures
By: /s/ Jeremy Green, Managing Member of Redmile Group, LLC		10/18/2021
^**Signature of Reporting Person		Date
/s/ Jeremy Green		10/18/2021
^**Signature of Reporting Person		Date